Phase entropy of gated SPECT-MPI for predicting major adverse cardiovascular events: incremental prognostic value beyond perfusion and function - Takeaways - MDSpire

Phase entropy of gated SPECT-MPI for predicting major adverse cardiovascular events: incremental prognostic value beyond perfusion and function

  • By

  • Yuxin Xiao

  • Yuting Zhao

  • Zhifang Wu

  • Xiaoli Zhang

  • Yuetao Wang

  • Minfu Yang

  • Sijin Li

  • July 7, 2026

  • 0 min

Share

  • 1

    Phase entropy from gated SPECT-MPI quantifies left ventricular mechanical synchrony and aids in cardiovascular risk stratification.

  • 2

    An U-shaped association between phase entropy and major adverse cardiovascular events was identified in a study of 1,674 coronary artery disease patients.

  • 3

    Patients with abnormal phase entropy values exhibited significantly lower survival rates compared to those with normal values.

  • 4

    Phase entropy remained an independent predictor of major adverse cardiovascular events after adjusting for total perfusion deficit and left ventricular ejection fraction.

  • 5

    Phase entropy thresholds ≤31% or >53% correlate with reduced survival and identify high-risk subgroups for intensified clinical monitoring.

Original Source(s)

Phase entropy of gated SPECT-MPI for predicting major adverse cardiovascular events: incremental prognostic value beyond perfusion and function

  • by Yuxin Xiao, Yuting Zhao, Zhifang Wu, Xiaoli Zhang, Yuetao Wang, Minfu Yang, Sijin Li

  • July 7, 2026

Related Content

GCS May Expand CTRCD Assessment

Award-winning ASE abstract highlights GCS when GLS assessment is limited by suboptimal apical windows.

Dr. Jordan Strom on ASE 2026 Scientific Sessions: AI, Access, and the Future of Echocardiography

As ASE convenes its 37th Scientific Sessions near Denver, the meeting will spotlight echocardiographic AI and big data, contrast-enhanced ultrasound, evolving guidelines, the Feigenbaum Lecture, and the future of the sonographer workforce.

Early-Phase Data Support Novel Contrast Agent

ASE 2026 data support further development of MVT-100 in pivotal trials.